Kevin DAmour - Jun 28, 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Chief Scientific Officer
Signature: /s/ Kevin D'Amour
Stock symbol: ERNA
Transactions as of: Jun 28, 2022
Transactions value $: -$3,363
Form type: 4
Date filed: 6/29/2022, 08:01 PM
Previous filing: Mar 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ERNA	Common Stock	Options Exercise		+17.6K			17.6K	Jun 28, 2022	Direct	F1
transaction	ERNA	Common Stock	Tax liability	-$3.36K	-6.08K	-34.58%	$0.55^*	11.5K	Jun 28, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	Restricted Stock Units	Options Exercise	$0	-17.6K	-25%	$0.00	52.7K	Jun 28, 2022	Common Stock	17.6K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit converts into one share of common stock.
F2	On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.